FoundationOne Heme was developed using technology, methods and computational algorithms developed by Foundation Medicine, combined with Memorial Sloan Kettering’s deep and vast expertise in clinical and laboratory research into hematologic malignancies.
Michael A. Foley, PhD, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute, Inc., a pioneering collaboration of Weill Cornell Medical College, The Rockefeller University and Memorial Sloan Kettering Cancer Center.
Renowned cancer biologist Joan Massagué, PhD, has been named Director of the Sloan Kettering Institute, one of the most dynamic and robust cancer research programs in the United States, and the research arm of Memorial Sloan Kettering Cancer Center.
Memorial Sloan Kettering Cancer Center has announced the appointment of surgical oncologist Richard Barakat to the new position of Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network and Alliance.
Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College have formed the pioneering Tri-Institutional Therapeutics Discovery Institute, Inc. and have partnered with Takeda Pharmaceutical Company, Ltd.
Memorial Sloan Kettering Cancer Center today launched a transformative initiative to improve the quality of cancer care and the lives of cancer patients. Hartford HealthCare, a multi-hospital health care system in Connecticut, was selected as a pioneering member of the newly formed Memorial Sloan Kettering Cancer Alliance.
For the first time, a genetic link specific to risk of childhood leukemia has been identified, according to a team of researchers from Memorial Sloan Kettering Cancer Center, St. Jude Children’s Research Hospital, University of Washington, and other institutions.